Expressions of EGFR, BRAF, and K-Ras Genes in Colorectal Carcinoma Tissues and Their Clinical Significances_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

西安交通大學醫學院第一附屬醫院普通外科（陜西西安 710061）;
Department of General Surgery, The First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China;

Corresponding?author：

Keywords：

Colorectal carcinoma; Epidermal growth factor receptor; BRAF; K-Ras; Immunohistochemistry

DOI：

10.7507/1007-9424.20160149

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To detect expressions of epidermal growth factor receptor (EGFR), BRAF, and K-Ras genes in colorectal carcinoma tissues and explore pathogenesis in colorectal carcinoma. Method The expressions of EGFR, BRAF, and K-Ras genes were detected in these 136 colorectal carcinoma tissues and their corresponding adjacent normal colorectal tissues by immunohistochemistry. Results The expressions of EGFR and BRAF in the colorectal carcinoma tissues were significantly higher than those in their corresponding adjacent normal colorectal tissues (P<0.05), but the expression of K-Ras had no significant difference between these two tissues (P>0.05). The expression of EGFR gene was related to the TNM stage, lymphatic metastasis, or degree of differentiation. The expression of BRAF gene was related to the TNM stage. The expression of K-Ras gene wasn,t related to the TNM stage, lymphatic metastasis, or degree of differentiation. The correlation analysis results showed that there was no relation among the EGFR, K-Ras, or BRAF expression. Conclusions Up-regulated of EGFR and BRAF gene expressions might be related to development of colorectal carcinoma, and role of K-Ras is unclear. Anti EGFR and BRAF target therapy might be benefited for patients with colorectal carcinoma.

Citation： 崔飛博, 陳南征, 鄭見寶, 張冠軍, 孫學軍, CUIFei-bo, CHENNan-zheng, ZHENGJian-bao, ZHANGGuan-jun, SUNXue-jun. Expressions of EGFR, BRAF, and K-Ras Genes in Colorectal Carcinoma Tissues and Their Clinical Significances. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(5): 556-560. doi: 10.7507/1007-9424.20160149 Copy

1.	?László L. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. Magy Onkol, 2010, 54(4):383-394.
2.	Xiang TX, Yuan Y, Li LL, et al. Aberrant promoter CpG methylation and its translational applications in breast cancer. Chin J Cancer, 2013, 32(1):12-20.
3.	Shadfan A, Hellebust A, Richards-Kortum R, et al. Confocal foveated endomicroscope for the detection of esophageal carcinoma. Biomed Opt Express, 2015, 6(7):2311-2324.
4.	Vukobrat-Bijedic Z, Husic-Selimovic A, Sofic A, et al. Cancer antigens (CEA and CA 19-9) as markers of advanced stage of colorectal carcinoma. Med Arch, 2013, 67(6):397-401.
5.	Man YG, Schwartz A, Levine PH, et al. BP1, a putative signature marker for inflammatory breast cancer and tumor aggressiveness. Cancer Biomark, 2009, 5(1):9-17.
6.	汪華, 賀靜, 閆曉紅, 等. BP1基因在結腸癌組織中的表達. 現代腫瘤醫學, 2015, 23(14):2041-2043.
7.	Park Y, Kim DS, Park KH, et al. RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. Onkologie, 2012, 35(11):673-682.
8.	劉會平, 楊磊, 丁彥青, 等. 多配體聚糖結合蛋白在大腸癌組織中的表達及其對預后的影響. 南方醫科大學學報, 2015, 35(7):1003-1007.
9.	Tsukahara T, Haniu H, Matsuda Y. Cyclic phosphatidic acid induces G0/G1 arrest, inhibits AKT phosphorylation, and downregulates cyclin D1 expression in colorectal cancer cells. Cell Mol Biol Lett, 2015, 20(1):38-47.
10.	Delavari A, Bishehsari F, Salimzadeh H, et al. Adenoma detection rates in an opportunistic screening colonoscopy program in Iran, a country with rising colorectal cancer incidence. BMC Gastroenterol, 2014, 14:196.
11.	Fu Y, Lian Y, Kim KS, et al. BP1 homeoprotein enhances metastatic potential in ER-negative breast cancer. J Cancer, 2010, (1):54-62.
12.	Del Vecchio Blanco G, Paoluzi OA, Sileri P, et al. Familial colorectal cancer screening:When and what to do? World J Gastroenterol, 2015, 21(26):7944-7953.
13.	Olsen AK, Coskun M, Bzorek M, et al. Regulation of APC and AXIN2 expression by intestinal tumor suppressor CDX2 in colon cancer cells. Carcinogenesis, 2013, 34(6):1361-1369.
14.	Man YG, Fu SW, Schwartz A, et al. Expression of BP1, a novel homeobox gene, correlates with breast cancer progression and invasion. Breast Cancer Res Treat, 2005, 90(3):241-247.
15.	Montenegro MF, Saez-Ayala M, Pinero-Madrona A, et al. Reactivation of the tumour suppressor RASSF1A in breast cancer by simultaneous targeting of DNA and E2F1 methylation. PLoS one, 2012, 7(12):e52231.
16.	Maeda C, Hidaka E, Mori Y, et al. Tumor diameter is an easy and useful predictor of recurrence in stage Ⅱ colorectal cancer. Dig Surg, 2015, 32(5):338-343.
17.	Trovik J, Wik E, Stefansson IM, et al. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res, 2011, 17(10):3368-3377.
18.	Chung MK, Kim HJ, Lee YS, et al. Hedgehog signaling regulates proliferation of prostate cancer cells via stathmin1. Clin Exp Med, 2010, 10(1):51-57.
19.	譚明, 戴春, 丁永斌, 等. syndecan21蛋白在胃癌中的表達及其意義. 中國普外基礎與臨床雜志, 2008, 15(12):910-913.
20.	姚宏亮, 楊竹林, 李永國, 等. 胃癌及癌旁組織中SKP2和p27蛋白表達及相互關系研究. 中國普外基礎與臨床雜志, 2007, 14(3):308-311.
21.	Rosell R. Expression profiles and clinicopathologic features in early resected non-small-cell lung cancer. EBioMedicine, 2014, 1(2-3):103-104.
22.	Liu X, Liu H, Liang J, et al. Stathmin is a potential molecular marker and target for the treatment of gastric cancer. Int J Clin Exp Med, 2015, 8(4):6502-6509.
23.	Wang F, Wang LX, Li SL, et al. Downregulation of stathmin is involved in malignant phenotype reversion and cell apoptosis in esophageal squamous cell carcinoma. J Surg Oncol, 2011, 103(7):704-715.
24.	Ojima T, Nezuka H, Earashi M, et al. Poor outcome of a patient with early double cancers of the stomach and sigmoid colon in which liver metastases were detected postoperatively. Gan To Kagaku Ryoho, 2014, 41(12):2425-2427.

1. ?László L. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. Magy Onkol, 2010, 54(4):383-394.
2. Xiang TX, Yuan Y, Li LL, et al. Aberrant promoter CpG methylation and its translational applications in breast cancer. Chin J Cancer, 2013, 32(1):12-20.
3. Shadfan A, Hellebust A, Richards-Kortum R, et al. Confocal foveated endomicroscope for the detection of esophageal carcinoma. Biomed Opt Express, 2015, 6(7):2311-2324.
4. Vukobrat-Bijedic Z, Husic-Selimovic A, Sofic A, et al. Cancer antigens (CEA and CA 19-9) as markers of advanced stage of colorectal carcinoma. Med Arch, 2013, 67(6):397-401.
5. Man YG, Schwartz A, Levine PH, et al. BP1, a putative signature marker for inflammatory breast cancer and tumor aggressiveness. Cancer Biomark, 2009, 5(1):9-17.
6. 汪華, 賀靜, 閆曉紅, 等. BP1基因在結腸癌組織中的表達. 現代腫瘤醫學, 2015, 23(14):2041-2043.
7. Park Y, Kim DS, Park KH, et al. RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. Onkologie, 2012, 35(11):673-682.
8. 劉會平, 楊磊, 丁彥青, 等. 多配體聚糖結合蛋白在大腸癌組織中的表達及其對預后的影響. 南方醫科大學學報, 2015, 35(7):1003-1007.
9. Tsukahara T, Haniu H, Matsuda Y. Cyclic phosphatidic acid induces G0/G1 arrest, inhibits AKT phosphorylation, and downregulates cyclin D1 expression in colorectal cancer cells. Cell Mol Biol Lett, 2015, 20(1):38-47.
10. Delavari A, Bishehsari F, Salimzadeh H, et al. Adenoma detection rates in an opportunistic screening colonoscopy program in Iran, a country with rising colorectal cancer incidence. BMC Gastroenterol, 2014, 14:196.
11. Fu Y, Lian Y, Kim KS, et al. BP1 homeoprotein enhances metastatic potential in ER-negative breast cancer. J Cancer, 2010, (1):54-62.
12. Del Vecchio Blanco G, Paoluzi OA, Sileri P, et al. Familial colorectal cancer screening:When and what to do? World J Gastroenterol, 2015, 21(26):7944-7953.
13. Olsen AK, Coskun M, Bzorek M, et al. Regulation of APC and AXIN2 expression by intestinal tumor suppressor CDX2 in colon cancer cells. Carcinogenesis, 2013, 34(6):1361-1369.
14. Man YG, Fu SW, Schwartz A, et al. Expression of BP1, a novel homeobox gene, correlates with breast cancer progression and invasion. Breast Cancer Res Treat, 2005, 90(3):241-247.
15. Montenegro MF, Saez-Ayala M, Pinero-Madrona A, et al. Reactivation of the tumour suppressor RASSF1A in breast cancer by simultaneous targeting of DNA and E2F1 methylation. PLoS one, 2012, 7(12):e52231.
16. Maeda C, Hidaka E, Mori Y, et al. Tumor diameter is an easy and useful predictor of recurrence in stage Ⅱ colorectal cancer. Dig Surg, 2015, 32(5):338-343.
17. Trovik J, Wik E, Stefansson IM, et al. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res, 2011, 17(10):3368-3377.
18. Chung MK, Kim HJ, Lee YS, et al. Hedgehog signaling regulates proliferation of prostate cancer cells via stathmin1. Clin Exp Med, 2010, 10(1):51-57.
19. 譚明, 戴春, 丁永斌, 等. syndecan21蛋白在胃癌中的表達及其意義. 中國普外基礎與臨床雜志, 2008, 15(12):910-913.
20. 姚宏亮, 楊竹林, 李永國, 等. 胃癌及癌旁組織中SKP2和p27蛋白表達及相互關系研究. 中國普外基礎與臨床雜志, 2007, 14(3):308-311.
21. Rosell R. Expression profiles and clinicopathologic features in early resected non-small-cell lung cancer. EBioMedicine, 2014, 1(2-3):103-104.
22. Liu X, Liu H, Liang J, et al. Stathmin is a potential molecular marker and target for the treatment of gastric cancer. Int J Clin Exp Med, 2015, 8(4):6502-6509.
23. Wang F, Wang LX, Li SL, et al. Downregulation of stathmin is involved in malignant phenotype reversion and cell apoptosis in esophageal squamous cell carcinoma. J Surg Oncol, 2011, 103(7):704-715.
24. Ojima T, Nezuka H, Earashi M, et al. Poor outcome of a patient with early double cancers of the stomach and sigmoid colon in which liver metastases were detected postoperatively. Gan To Kagaku Ryoho, 2014, 41(12):2425-2427.

Previous Article
Significance of Glucocorticoid for Rat Liver Transplantation Model
Next Article
胃富于細胞型神經鞘瘤1例報道

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expressions of EGFR, BRAF, and K-Ras Genes in Colorectal Carcinoma Tissues and Their Clinical Significances

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content